dupilumab – media

Sanofi, Regeneron’s biologic shines again in asthma trial

Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
- Source: Pharmatimes
- 1,089
- November 3, 2017
asthma Clinical Trial dupilumab
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 563
- September 12, 2017
asthma Clinical Trials dupilumab Phase

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.